Addyi (Flibanserin) Safety Signals and FDA Actions: A Clinical Timeline

How Flibanserin Works: Mechanism of Action

Flibanserin is not a hormone. It is a centrally acting serotonergic agent that modulates neurotransmitter balance in the prefrontal cortex and other brain regions involved in sexual desire. The drug functions as a full agonist at the serotonin 5-HT1A receptor and an antagonist at the serotonin 5-HT2A receptor 1.

Serotonin, Dopamine, and Norepinephrine

The pharmacodynamic result of this dual serotonergic action is a downstream increase in dopamine and norepinephrine release while reducing serotonin signaling in specific circuits. This neurochemical shift is thought to restore excitatory/inhibitory balance in sexual desire pathways 2. Early in its development, flibanserin was studied as an antidepressant. It failed to show efficacy for depression but produced an unexpected signal: women in clinical trials reported increased sexual desire.

Why Bedtime Dosing Matters

The drug causes significant sedation and dizziness. Taking flibanserin at bedtime reduces the window of impairment during waking hours. The 100 mg tablet is taken once nightly, and steady-state plasma concentrations are reached within 3 to 4 days 1. Patients who miss a dose should skip it entirely and resume the next evening. Doubling the dose increases adverse event risk without additional benefit.

Onset and Duration of Effect

Clinical benefit, measured by satisfying sexual events (SSEs) and desire scores, does not appear immediately. In the BEGONIA trial (N=1,087), statistically significant separation from placebo on the Female Sexual Function Index desire domain emerged by week 4, with maximum effect observed around week 8 3. Clinicians should counsel patients that a minimum 8-week trial is appropriate before determining treatment failure.

FDA Rejection Timeline: 2010 and 2013

Few drugs have faced the regulatory path flibanserin endured. The FDA rejected the drug twice on safety grounds before a third review led to conditional approval.

The 2010 Complete Response Letter

Sprout Pharmaceuticals (then a subsidiary of Boehringer Ingelheim) submitted its first New Drug Application in 2009. An FDA Advisory Committee voted 11-0 against approval in June 2010, citing modest efficacy and a side effect profile dominated by dizziness, somnolence, and nausea 4. The committee stated the benefit-risk ratio did not favor approval given the small treatment effect size. The FDA issued a Complete Response Letter requesting additional efficacy and safety data.

The 2013 Complete Response Letter

Sprout resubmitted in 2013 with additional analyses. The FDA again declined, requesting a driving impairment study and further characterization of CNS depression risk 5. The agency specifically flagged concerns about next-morning sedation and the drug's interaction with alcohol and CYP3A4 inhibitors. This second rejection pushed the drug's regulatory journey past the five-year mark.

The 2015 Advisory Committee and Approval

In June 2015, the FDA's Bone, Reproductive, and Urologic Drugs Advisory Committee voted 18-6 in favor of approval, a dramatic reversal from 2010 4. The shift reflected both additional clinical data and public advocacy by patient groups arguing that women lacked pharmacologic options for sexual dysfunction. On August 18, 2015, the FDA approved flibanserin with a boxed warning and REMS, the most restrictive conditions for a non-opioid drug at the time. FDA Commissioner Dr. Janet Woodcock stated: "The FDA strives to protect and advance the health of women, and we are committed to supporting the development of safe and effective treatments for female sexual dysfunction."

Key Trial Efficacy and Safety Data

Three Phase III trials established flibanserin's efficacy and safety profile. All enrolled premenopausal women with generalized, acquired HSDD.

VIOLET, DAISY, and BEGONIA Results

In the BEGONIA trial (N=1,087), flibanserin 100 mg at bedtime produced a mean increase of 0.5 SSEs per month over placebo (2.5 vs. 2.0 events), a statistically significant but numerically modest difference (P<0.05) 3. The VIOLET trial (N=1,247) showed a 0.7 SSE increase versus placebo 6. DAISY (N=1,188) confirmed these findings with a 0.6 SSE improvement 7.

Across all three trials, the most frequently reported adverse events were dizziness (11.4% vs. 2.2% placebo), somnolence (11.2% vs. 3.0% placebo), and nausea (10.4% vs. 3.9% placebo) 4. Discontinuation rates due to adverse events ranged from 9.6% to 13.0% in the flibanserin arms versus 3.7% to 5.0% for placebo.

Pooled Safety Analysis

A pooled analysis of 11,187 patient-years of exposure across all clinical trials identified syncope in 0.4% of flibanserin-treated patients versus 0.0% in placebo groups 5. Hypotension requiring medical attention was reported in 0.2% of patients. These events were concentrated in the first two weeks of treatment and in patients who were also using moderate CYP3A4 inhibitors.

The Alcohol Interaction: Black Box Warning

The alcohol-flibanserin interaction drove the most intense regulatory scrutiny and shaped the drug's REMS program.

Preapproval Alcohol Studies

In a pharmacokinetic interaction study, 25 participants (23 male, 2 female) consumed alcohol while taking flibanserin. Of the 23 men, 4 experienced symptomatic hypotension or syncope requiring positioning intervention 5. The FDA flagged the predominantly male study population as a limitation, noting that women may metabolize alcohol differently and could face a different risk magnitude.

The Boxed Warning Language

The labeling states: "The use of flibanserin and alcohol increases the risk of severe hypotension and syncope. Counsel patients not to consume alcohol while taking flibanserin" 4. This was among the first boxed warnings on a non-opioid, non-oncologic drug explicitly tied to a food/beverage interaction rather than a drug-drug interaction.

The MERIT Post-Marketing Study

The FDA required Sprout (later acquired by Valeant, then reorganized under Sprout again) to conduct a post-marketing study of the alcohol interaction in women. The MERIT study enrolled 217 premenopausal women who consumed alcohol while taking flibanserin at steady state 8. Results showed that 4.8% of women experienced clinically significant drops in systolic blood pressure when combining flibanserin with moderate alcohol intake, compared with 0.7% on placebo. No syncope events requiring medical intervention occurred. Based on these data, the FDA removed the alcohol contraindication from the REMS in April 2019, replacing it with a warning to "limit alcohol use" rather than avoid it completely 9.

REMS Program: Requirements and Modifications

The flibanserin REMS is one of the most detailed post-approval monitoring frameworks for a non-controlled substance.

Original 2015 REMS Structure

At approval, the REMS required three elements: a medication guide distributed at every dispensing, a prescriber certification program (Elements to Assure Safe Use), and pharmacy certification 5. Prescribers had to complete an online training module and enroll in the program before writing a prescription. Pharmacies had to verify prescriber certification before dispensing. Patients were required to sign an acknowledgment form confirming they understood the alcohol interaction risk.

2019 REMS Modification

In April 2019, the FDA ordered modifications based on MERIT data and real-world dispensing experience 9. The updated REMS eliminated the prescriber and pharmacy certification requirements, removed the mandatory patient-prescriber interaction form, and downgraded the alcohol warning from "contraindicated" to "limit use." Dr. Janet Woodcock noted at the time: "Based on our review of the data, we determined that the original REMS requirements were unnecessarily burdensome and were not necessary to ensure that the drug's benefits outweigh its risks."

Current REMS Components

The current REMS retains only the medication guide. Prescribers no longer need to enroll in a certification program. This simplified structure brought flibanserin's dispensing workflow closer to standard prescription medications, though the boxed warning for hypotension and syncope remains on the label 9.

CYP3A4 Drug Interactions: A Persistent Safety Signal

Beyond alcohol, the most clinically significant drug interactions involve the CYP3A4 metabolic pathway.

Contraindicated Combinations

Flibanserin is extensively metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, certain HIV protease inhibitors) increases flibanserin AUC by approximately 4.5-fold 1. This degree of exposure magnification pushes hypotension and syncope risk to unacceptable levels. The label lists strong CYP3A4 inhibitors as contraindicated.

Moderate CYP3A4 Inhibitors

Moderate inhibitors such as fluconazole, erythromycin, and grapefruit juice increase flibanserin AUC by roughly 2-fold 5. The labeling recommends against concomitant use but does not list these as absolute contraindications. In practice, many prescribers treat moderate CYP3A4 inhibitors as a relative contraindication given the syncope signal. Patients starting or stopping a moderate CYP3A4 inhibitor should wait at least 2 weeks before initiating or resuming flibanserin.

Hepatic Impairment

Flibanserin is contraindicated in patients with hepatic impairment of any severity. Because CYP3A4 activity is reduced in liver disease, drug exposure increases substantially 4. A pharmacokinetic study in patients with Child-Pugh class A (mild) hepatic impairment showed a 4.5-fold increase in AUC, comparable to the effect of strong CYP3A4 inhibitor co-administration.

Post-Marketing Surveillance and FAERS Data

Since approval, the FDA Adverse Event Reporting System (FAERS) has accumulated over a decade of real-world safety data on flibanserin.

Top Reported Adverse Events

FAERS queries through 2025 show dizziness, syncope, somnolence, and nausea as the most frequently reported events, consistent with the clinical trial profile 10. No new safety signals (e.g., hepatotoxicity, cardiac arrhythmia, or suicidality) have emerged beyond those characterized during pre-approval development. The absence of unexpected signals over 10+ years of surveillance provides some reassurance, though the drug's low prescription volume limits the statistical power for detecting rare events.

Prescription Volume Context

Flibanserin has not achieved widespread adoption. Estimated U.S. Prescriptions have remained under 10,000 per quarter since launch, a fraction of the volume seen with phosphodiesterase-5 inhibitors for male sexual dysfunction 10. The REMS burden (particularly pre-2019), modest efficacy, and alcohol restriction all contributed to limited uptake. Low utilization means rare adverse events may remain undetected in voluntary reporting systems.

Ongoing FDA Requirements

The FDA continues to require periodic safety update reports from the manufacturer. No additional labeling changes have been mandated since the 2019 REMS modification. The drug remains classified as non-controlled under the DEA schedule, and no abuse or dependence signal has been identified 5.

Clinical Monitoring Recommendations

Prescribers initiating flibanserin should follow a structured monitoring approach during the first 8 weeks of therapy.

Baseline Assessment

Obtain a medication reconciliation with specific attention to CYP3A4 inhibitors (prescription, over-the-counter, and herbal products including St. John's wort). Confirm the patient has no hepatic impairment via clinical history and, if clinically indicated, liver function tests. Screen alcohol use with a validated instrument such as the AUDIT-C. Patients consuming more than 3 drinks per week may face higher hypotension risk 8.

First Two Weeks

Contact the patient at day 7 and day 14 to assess for dizziness, presyncope, or excessive daytime somnolence. Blood pressure monitoring is warranted in patients on antihypertensives or with baseline systolic values below 110 mmHg. If syncope occurs, discontinue flibanserin and do not rechallenge 4.

Week 8 Efficacy Check

Reassess desire using the FSFI desire domain or a patient-reported outcome measure. If no clinically meaningful improvement is present by 8 weeks, the drug should be discontinued. Continued treatment in the absence of benefit exposes the patient to side effect risk without corresponding gain. There is no evidence supporting dose escalation beyond 100 mg nightly.